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ABSTRACT
Oleoylethanolamide (OEA) is a satiety factor that controls motivational responses to dietary fat. Here we show that
alcohol administration causes the release of OEA in rodents, which in turn reduces alcohol consumption by engaging
peroxisome proliferator-activated receptor-alpha (PPAR-α). This effect appears to rely on peripheral signaling mecha-
nisms as alcohol self-administration is unaltered by intracerebral PPAR-α agonist administration, and the lesion of
sensory afferent fibers (by capsaicin) abrogates the effect of systemically administered OEA on alcohol intake. Addi-
tionally, OEA is shown to block cue-induced reinstatement of alcohol-seeking behavior (an animal model of relapse)
and reduce the severity of somatic withdrawal symptoms in alcohol-dependent animals. Collectively, these findings
demonstrate a homeostatic role for OEA signaling in the behavioral effects of alcohol exposure and highlight OEA as a
novel therapeutic target for alcohol use disorders and alcoholism.
Keywords Alcohol self-administration, alcoholism, oleoylethanolamide, PPAR-α, relapse.
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INTRODUCTION
Oleoylethanolamide (OEA) is a bioactive lipid mediator
that belongs to the fatty acid ethanolamide (FAE) family.
Although OEA is a structural analogue of the
endocannabinoid arachidonoyl ethanolamide (AEA or
anandamide), it neither binds to nor activates cannabi-
noid receptors (Rodríguez de Fonseca et al. 2001; Fu et al.
2003). Indeed, OEA exerts a number of pharmacological
effects, including the induction of satiety, the reduction of
bodyweight gain and the stimulation of lipolysis, through
the activation of the peroxisome proliferator-activated
receptor-alpha (PPAR-α) (Rodríguez de Fonseca et al.
2001; Fu et al. 2003; Guzmán et al. 2004). OEA binds to
this nuclear receptorwithhighaffinity and themajority of
its effects are absent in mice lacking PPAR-α (Fu et al.
2003; Guzmán et al. 2004).
There is a growing body of evidence supporting the
idea that OEA might serve as a homeostatic signal that
controls multiple aspects of the intake and metabolism of
highly caloric fat-containing foods (for review, see
Piomelli 2003). OEA regulates energy expenditure and
fat utilization primarily through its involvement in the
modulation of fat appetite (Schwartz et al. 2008), lipid
and glucose metabolism (Fu et al. 2003; González-Yanes
et al. 2005; Serrano et al. 2006, 2011; Martínez de
Ubago et al. 2009) and the reward associated with high-
calorie intake (Tellez et al. 2013). OEA is generated in the
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intestine upon the arrival of fat-containing food through
a process controlled by the sympathetic nervous system
(Fu et al. 2007, 2011). By engaging PPAR-α, the OEA
formed in the intestine activates peripheral sensory
systems located in the vagus nerve that convey informa-
tion to the nucleus of the solitary tract and gut peptides
that are released into the blood stream to regulate the
hypothalamic integrative networks that control energy
expenditure (Gaetani et al. 2010; Serrano et al. 2011).
Additionally, in vitro and in vivo studies have demon-
strated that OEA stimulates lipolysis and fatty acid oxida-
tion through a mechanism that involves PPAR-α
(Guzmán et al. 2004; Suárez et al. 2014).
In addition to its role as a homeostatic signal that
controls energy expenditure, growing evidence suggests
that OEA might influence motivational processes
through its ability to modulate reward systems in the
brain. Recent reports (Tellez et al. 2013) have shown
that, by modulating gut sensory nerve terminals of the
vagus nerve, intestinal OEA affects the dopaminergic
activity that is induced by infusion of either low- or high-
calorie emulsions. Indeed, exogenously administered
OEA might restore the dopaminergic deficiency that is
associated with high-fat diets, which indicates that, in
addition to the control of appetite, OEA might serve as a
homeostatic signal that is associated with the motiva-
tional drives involved in food selection (Tellez et al. 2013).
This finding aligns with the recent description of the
ability of OEA to modulate the dopaminergic responses
associated with nicotine self-administration (Melis et al.
2008; Mascia et al. 2011). Indeed, OEA not only modu-
lates mesocorticolimbic dopaminergic neurons but also
blocks both nicotine-induced reward and nicotine-
induced nicotine self-administration through a PPAR-α-
dependent mechanism (Mascia et al. 2011). Considering
the presence of the OEA-signaling machinery in the
brain, particularly in the hippocampus (Rivera et al.
2014) and the description of OEA’s ability to modulate
memory consolidation (Campolongo et al. 2009), the
homeostatic role of this bioactive lipid extends to both
motivational and cognitive processes that are associated
with the hedonic valence of actions.
Given that ethanol is both a high-calorie food and a
drug of abuse that is capable of modulating reward, we
hypothesized that OEA might interfere with the endog-
enous signals activated by alcohol. There is compelling
evidence that lipid mediators of the FAE family are
involved in alcohol dependence (Rodríguez de Fonseca
et al. 2005). Studies have shown that acute administra-
tion of intoxicating doses of ethanol inhibits the in vivo
formation of AEA in the rat brain (Ferrer et al. 2007),
whereas low to moderate doses enhance its release in vivo
and in vitro (Basavarajappa, Ninan & Arancio 2008;
Ceccarini et al. 2013). Chronic ethanol exposure is asso-
ciated with increases in the formation of AEA and FAE
precursors. Although AEA and CB1 receptors have been
shown to mediate some of the pharmacological and
behavioral aspects of alcohol use (Basavarajappa &
Hungund 2002; Rodríguez de Fonseca et al. 2005; Ferrer
et al. 2007), the effects of non-cannabinoid FAEs such as
OEA have been poorly characterized, and direct experi-
mental evidence regarding the behavioral significance
of the OEA–PPAR-α interaction on ethanol-related
behaviors is still lacking. To fill this knowledge gap, we
evaluated the potential roles of OEA and PPAR-α in
alcohol-seeking behavior (ethanol self-administration
and relapse) and monitored the changes in OEA produc-
tion during acute and chronic ethanol exposure.
MATERIALS AND METHODS
Animals
The experiments were performed on male Wistar rats
(Charles River, Barcelona, Spain). In vivo microdialysis
studies were performed on adult C57Bl/6 male mice
(Jackson Laboratory, Bar Harbor, ME, USA). All of the
procedures involving the care and use of animals were
conducted in adherence with the European Directive
2010/63/EU on the protection of animals used for scien-
tific purposes and Spanish regulations (Real Decreto
53/2013 and 178/2004, Ley 32/2007 and 9/2003 and
Decreto 320/2010) for the care and use of laboratory
animals.
Drugs
OEA was synthesized as previously described (Rodríguez
de Fonseca et al. 2001). OEA was dissolved in a vehicle of
5 percent Tween-80 (Sigma Aldrich Co., St. Louis, MO,
USA) and 95 percent sterile saline and administered i.p.
in a volume of 1 ml/kg body weight. The following doses
of OEA were used: (1) 1, 5 and 20 mg/kg for the self-
administration and reinstatement studies; (2) 1 and
5 mg/kg for the ethanol deprivation study; and (3)
5 mg/kg for the evaluation of alcohol withdrawal signs.
Wy-14643 (Tocris Bioscience, Bristol, UK) was mixed
in a vehicle of 10 percent DMSO, 10 percent Tween-80
and 80 percent sterile saline. Wy-14643 was adminis-
tered i.p. in a volume of 1 ml/kg body weight and by i.c.v.
injection in a total volume of 5 μl. The following doses
were used: (1) 5, 20 and 40 mg/kg for the self-
administration and reinstatement studies; (2) 20 mg/kg
for the ethanol deprivation study; (3) 5 and 20 mg/kg for
the locomotor and anxiety tests; and (4) 1 and 10 μg for
central administrations.
The PPAR-α antagonist GW6471 (Tocris Bioscience)
was dissolved in a vehicle of 5 percent Tween-80 and 95
percent sterile saline and administered i.p. at a dose of
1 mg/kg in a volume of 1 ml/kg body weight.
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TheorphanG-protein coupled receptor 119 (GPR119)
antagonist PSN375963 (Tocris Bioscience) was dissolved
in a vehicle of 5 percent Tween-80 and 95 percent sterile
saline and administered i.p. at doses of 0.1 and 10 mg/kg
in a volume of 1 ml/kg body weight.
The cannabinoidCB1 receptor antagonist SR141716A
(rimonabant) was purchased from Sanofi-Aventis (Sanofi
S.A., Paris, France). Rimonabantwas suspendedwith two
to three drops of Tween-80 in sterile saline as the vehicle.
Rimonabantwas administered i.p. at a dose of 3 mg/kg in
a volume of 1 ml/kg body weight.
The neurotoxin capsaicin was purchased from Sigma-
Aldrich Co. and dissolved in 5 percent Tween-80, 5
percent propylene glycol and 90 percent sterile saline.
Deafferentation
Capsaicin was administered subcutaneously (12.5 mg/
ml) (Kaneko, Kaunitz & Tache 1998) to rats that were
anesthetized with ethyl ether. The total dose of capsaicin
(125 mg/kg) was divided into three injections (25 mg/kg
in the morning, 50 mg/kg in the afternoon and
50 mg/kg on the following day). The control rats received
vehicle injections. The experiments were performed 10
days after capsaicin treatment in rats that had lost the
corneal chemosensory reflex (i.e. eye wiping for 1–3
minutes after the application of 0.1 percent ammonium
hydroxide into one eye).
Intracerebral infusion cannulas and intra-NAc
OEA testing
For the intracerebral infusions, stainless steel guide can-
nulas aimed at the NAc were implanted in the rats.
Animals that had previously been trained to self-
administer 10 percent ethanol were anesthetized with an
isoflurane/oxygen vapor mixture (1.5–2.0 percent) and
implanted with bilateral microinfusion guide cannulas
(12 mm, 22 gauge, stainless steel) that terminated
3 mm above the ventral surface of the NAc [from
bregma: anteroposterior (AP), +1.6 mm; mediolateral
(ML), ±2.0 mm; and dorsoventral (DV), −5.0 mm from
dura]. These coordinates provided injector placements at
the interface between the shell and core of the NAc. A
minimum of 5 days of post-operative recovery was
allowed before the evaluation of the effect of the local
administration of OEA on ethanol self-administration.
After the establishment of stable self-administration
behavior, the animals received an initial microinjector
insertion (no liquid infusion) immediately before self-
administration to acclimate them to the procedure and to
produce the initial tissue damage from the insertion of the
injector. Subsequently, vehicle or OEA infusions were
made via bilateral 33-gaugemicroinjectors that extended
2 mm beyond the tips of the guide cannulas. Infusions of
1 μl per side were made over a 2-minute period, and the
removal of the injector was delayed by an additional 1
minute to allow for drug diffusion. The stylets were then
replaced in the guide cannulas, and the rats were allowed
immediate access to the ethanol self-administration para-
digm.The effects produced by vehicle or 1 μgOEA per side
were evaluated.
Surgery procedure and i.c.v. drug injection
For the i.c.v. injections, stainless steel guide cannulas
aimed at the lateral ventricle were implanted in the rats.
The animals were anesthetized with an isoflurane/
oxygen vapor mixture (1.5–2.0 percent) and placed on a
stereotaxic apparatus (David Kopf Instruments, Tujunga,
CA, USA) with the incisor bar set at 5 mm above the
interaural line. A guide cannula (7 mm, 23 gauge) was
secured to the skull with two stainless steel screws and
dental cement and was closed with 30-gauge obturators.
The implantation coordinates calculated relative to
bregma as follows: AP +0.6 mm, ML ±2.0 mm and DV
−3.2 mm from the surface of the skull. These coordinates
placed the cannula 1 mm above the ventricle. After 7
days of a post-surgical recovery period, cannula patency
was confirmed by the gravity-fed flow of isotonic saline
through a stainless steel injector (8 mm, 30 gauge) that
was inserted within the guide to 1 mmbeyond its tip. This
procedure allowed the animals to become familiar with
the injection technique.
For the i.c.v. administration of Wy-14643, the stylet
was removed from the guide cannula of each rat and an
injector connected to70 cmof calibratedpolyethylene-10
tubingwas lowered into theventricle.The tubingwas then
raised until the flow began, and 5 μl of drug solution at
doses of 1 and 10 μg was infused over a 30- to 60-second
period. The injector was left in the guide cannula for an
additional 30 seconds and then removed. The stylet was
immediately replaced. The animals were tested 5minutes
after injection. The i.c.v. cannula placements were evalu-
ated after each experiment via dye injection. Only rats
with proper i.c.v. placements were included in the data
analysis.
Acute ethanol administration: blood and
tissue sampling
Ethanol was dissolved in sterile 0.9 percent (w/v) saline
and administered i.p. at a dose of 4 g/kg.
For the blood and visceral sampling, a group of
animals was anaesthetizedwithmethoxyflurane at 0, 45,
90 or 240 minutes after the injection of ethanol. Blood
(2 ml) was collected from the heart of the animal with a
syringe filled with 1 ml of Krebs–Tris buffer (136 mM
NaCl, 6 mM KCl, 1.2 mM MgCl2, 2.5 mM CaCl2, 10 mM
glucose and 20 mM Trizma base, pH 7.4). The blood
Oleoylethanolamide and alcohol
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samples were centrifuged in Accuspin tubes (Sigma-
Aldrich Co.) at 800× g for 10 minutes at 22°C. The
samples were obtained from the small intestine and the
liver, and were frozen immediately on solid CO2.
The brains were collected from a second group of
animals after rapid decapitation and frozen immediately
on solid CO2. The frozen brains were placed in acrylic rat
brain matrices, and 2-mm thick slices were obtained
using brain matrix razor blades. The NAc and cerebellum
were dissected in 2-mm thick frozen coronal slices that
corresponded to plates 9–13 (NAc) and 56–65 (cerebel-
lum) of the atlas of Paxinos & Watson (1998).
Chronic ethanol administration and ethanol
withdrawal: collection of rat plasma
The regular chow diet was removed and replaced with a
liquid diet consisting of chocolate-flavored boost liquid
nutritional supplement fortified with vitamins and min-
erals. The rats were separated into two groups: the
ethanol group received a diet containing 10 percent
(w/v) ethanol and the control group received an
ethanol-free diet supplemented with sucrose to equalize
the caloric intake across the two groups. The diet was
available 24 hours for 21 days. On the final liquid diet
day, the animals were maintained in their home cage
with access to the regular chow diet and water. Blood
samples were drawn at 0, 6 and 12 hours after the
removal of the liquid diet.
Ethanol withdrawal behaviors
Beginning 6 hours after the diet with ethanol was with-
drawn, the animals were evaluated at hourly intervals.
The rats were observed for 5 minutes, and ethanol with-
drawal signs, including general activity, shakes, tremors,
mobility, spontaneous convulsive seizures and rigidity,
were scored.
Plasma ethanol levels
The plasma ethanol levels were enzymatically measured
using a commercial kit (Sigma-Aldrich Co.). The assays
were run according to the manufacturer’s instructions.
High-performance liquid chromatography–mass
spectrometry (HPLC-MS) analyses of the tissue content
of OEA
OEA was extracted with methanol/chloroform (1:2, v/v)
from the plasma, peripheral tissues (small intestine and
liver) and brain areas (NAc and cerebellum). Samples
were injected into an HP 1100 Series HPLC-MS system
equipped with a Hewlett-Packard OctaDecyl Silica
Hypersil column (100 × 4.6 mm i.d., 5 μm). The esti-
mated recovery of OEAwas 99.7 ± 0.3 percent. Reversed
phase separations were performed using linear increases
of methanol in water at a flow rate of 0.5 ml/min as
previously described (Giuffrida, Rodríguez de Fonseca &
Piomelli 2000). The MS analyses were performed in the
positive ionization mode with an electrospray ion source.
For the quantitative analyses, diagnostic fragments cor-
responding to the protonated molecules [(M + H)+] and
the sodium adducts of the molecular ions [(M + Na)+]
were followed in the selected ion monitoring mode.
System control and data evaluation were conducted
using an on-line system software (HP Chemstation
Software, Hewlett-Packard, Palo Alto, CA, USA).
In vivo microdialysis studies
Mice received i.p. injections of ethanol (2 g/kg) every
other day over 2weeks (see the experimental design in the
Supporting Information). The day before the last injec-
tion, the mice were each implanted with a single
microdialysis probe into the NAc that was secured to the
skull with dental cement. The stereotaxic coordinates
from bregma were +1.5 mm AP, ±0.8 mm ML and
−5.0 mm DV (from the skull) (Paxinos & Watson 1998),
and the microdialysis probes employed in 1-mm length
active membranes (polyethyl sulfone membrane, 15 kDa
cut off from SciPro Inc., Sanborn, NY, USA).
The probes were perfused with artificial cerebrospinal
fluid, which was delivered at a flow rate of 0.6 μL/min
and was composed of the following (in mM): 149 NaCl,
2.8 KCl, 1.2 CaCl2, 1.2 MgCl2, 0.25 ascorbic acid,
5.4 D-glucose and 30 percent (w/v) hydroxypropyl-β-
cyclodextrin (HP-β-CD). The inclusion of the HP-β-CD in
the perfusate provided a substantial increase in the dialy-
sis recovery of OEA. Approximately 12–16 hours after
probe implantation, dialysate samples were collected at
10-minute intervals. Following a baseline dialysate col-
lection (60 minutes), mice were injected with ethanol
(2 g/kg; i.p.) and dialysates collected for 120 minutes.
Dialysate samples were frozen on dry ice and stored at
−80°C until analysis for OEA content using liquid chro-
matography coupled withmass spectrometry (Caillé et al.
2007).
Proper placement of the active dialysis membrane
within the NAcwas histologically verified for each experi-
ment. The brains were sliced (20 μm), and the place-
ments of the microdialysis probes were verified using the
atlas of Paxinos (Paxinos & Watson 1998).
Operant training for liquid reinforcers
Training and testing were conducted in standard operant
chambers that were located in sound-attenuating, venti-
lated environmental cubicles. Each chamber was
equipped with a drinking reservoir (volume capacity:
0.10 ml) positioned 4 cm above the grid floor in the
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center of the front panel of the chamber, and two retract-
able levers were located 3 cm to the right and left of the
drinking receptacle. Auditory and visual stimuli were
presented via a speaker and a light located on the front
panel. A microcomputer controlled the delivery of fluids,
presentation of auditory and visual stimuli, and record-
ing of the behavioral data. The rats were trained to self-
administer 10 percent (v/v) ethanol, 10 percent sucrose
or water in 30-minute daily sessions on a fixed ratio 1
schedule of reinforcement in which each response
resulted in the delivery of 0.1 ml of fluid as previously
described (Weiss et al. 1993). Briefly, for the first 3 days of
training, water availability in the home cage was
restricted to 2 hours per day to facilitate the acquisition of
operant responding for a liquid reinforcer. During this
time, lever pressing that was reinforced with a 0.2
percent (w/v) saccharin or a 10 percent (w/v) sucrose
solution was established. At this point, water was
made freely available, and saccharin/sucrose self-
administration training continued until the animals
reached stable baseline responding. The rats in the
saccharin-trained group were then trained to self-
administer ethanol using a modification of the sucrose-
fading procedure (Samson 1986) that employed
saccharin rather than sucrose (Weiss et al. 1993). During
the first 6 days of this ethanol initiation phase, a 5
percent (w/v) ethanol solution containing 0.2 percent
saccharin (w/v) was available to the rats. Beginning on
day 7, the concentration of ethanol gradually increased
from 5 to 8 percent and finally to 10 percent (w/v),
whereas the concentration of saccharin correspondingly
decreased to 0 percent. At the beginning of the
saccharin-fading procedure, a second, inactive lever was
introduced. During all training and testing phases, the
responses on this lever were recorded as a measure of
non-specific behavioral activation, but they had no pro-
grammed consequences (Cippitelli et al. 2005).
Sucrose self-administration
Following completion of the sucrose training, Wistar rats
were used to study the effects of OEA (0, 1, 5 and 20 mg/
kg) when administered 30 minutes prior to a self-
administration session. These experiments were
conducted every fourth day using a Latin square coun-
terbalanced design. Responding at the inactive lever was
recorded throughout the experiment to monitor non-
specific behavioral effects.
Ethanol self-administration
Following the completion of the saccharin-fading proce-
dure, Wistar rats were trained in sessions of 30 minutes/
day to lever press for 10 percent ethanol (0.1 ml per
response) until stable baseline responding was reached.
We studied the effects of OEA (0, 1, 5 and 20 mg/kg) or
Wy-14643 (0, 5, 20 and 40 mg/kg) when administered
30 minutes prior to the self-administration sessions.
These experiments were conducted every fourth day
using a Latin square counterbalanced design. Respond-
ing at the inactive lever was recorded throughout the
experiment to monitor non-specific behavioral effects.
Alcohol deprivation
Rats were trained to self-administer 10 percent ethanol.
Following 3 days of baseline responding sessions, the rats
were deprived of ethanol for five consecutive days (no
operant sessions). At the end of the fifth day of the dep-
rivation phase, the rats were distributed into four groups
that were treated with vehicle, OEA (1 and 5 mg/kg) or
Wy-14643 (20 mg/kg) 30 minutes before the test
session.
Reinstatement of ethanol-seeking behavior
Conditioning phase
At the completion of the fading procedure, the animals
were trained to discriminate between 10 percent ethanol
and water in 30-minute daily sessions. Beginning with
self-administration training at the 10 percent ethanol
concentration, discriminative stimuli that were predictive
of ethanol or water availability were presented during the
ethanol and water self-administration sessions, respec-
tively. The discriminative stimulus for ethanol consisted of
an orange extract odor (S+), and thewater availability (i.e.
no reward) was signaled with an anise extract (S−). The
olfactory stimuli were generated by placing six to eight
drops of the respective extract into the bedding of the
operant chamber. Additionally, each lever press resulting
in the delivery of ethanol was paired with the illumina-
tion of the chamber’s house light for 5 seconds (CS+). The
corresponding cue during the water sessions was a
5-second tone (70 dB; CS−). During the presentation of
these stimuli, a 5-second time out period was in effect;
during this period responses were recorded but not rein-
forced. The olfactory stimuli that served as the S+ or S− for
ethanol or water availability were introduced 1 minute
before the extension of the levers and remained present
throughout the 30-minute sessions. The bedding of the
chamber was changed, and the bedding trays were
cleaned between sessions. The rats were only given
ethanol sessions during the first 3 days of the condition-
ing phase. Subsequently, ethanol and water sessions were
conducted in a random order across training days with
the constraint that all of the rats received totals of 10
ethanol and 10 water sessions.
Oleoylethanolamide and alcohol
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Extinction phase
After the last conditioning day, the rats were subjected to
30-minute extinction sessions for 15 consecutive days.
During this phase, the sessions began with the extension
of the levers without the presentation of the discrimina-
tive stimuli. Responses at the lever activated the delivery
mechanism but did not result in the delivery of liquids or
the presentation of the response-contingent cues (i.e. the
house light or tone).
Reinstatement testing
The reinstatement tests began the day after the last
extinction session. These tests lasted 30 minutes, and the
conditions were identical to those of the conditioning
phase with the exception that the alcohol and water were
not available. The sessions were initiated by the extension
of both levers and the presentation of either the ethanol
(S+)- or water (S−)-paired stimulus. The respective dis-
criminative stimulus remained present during the entire
session, and responses at the previously active lever were
followed by the activation of the delivery mechanism and
a 5-second presentation of the CS+ in the S+ condition or
the CS− in the S− condition.The animals were tested under
in the S+/CS+ condition on day 1 and in the S−/CS− condi-
tion on day 2. Subsequently, reinstatement experiments
were conducted every fourth day (on days 6, 10 and 14),
and OEA or Wy-14643 was administered 30 minutes
prior to these sessions. Responding at the inactive lever
was constantly recorded to monitor possible non-specific
behavioral effects.
Two-bottle choice test
The two-bottle choice method was used to determine the
voluntary ethanol consumption of rats. The animals
were individually housed in standard cages and allowed
to acclimate for 1 week. Each rat had continuous access
to two identical bottles, one of which always contained
tap water. Food was available ad libitum. After 4 days of
water consumption (both bottles), a choice between 10
percent (v/v) ethanol and water was offered for several
days until reaching a stable baseline. The bottle positions
were changed every day to avoid position preferences. On
the test day, animals received an administration of
vehicle, PSN375963, OEA and GW6471 or a combina-
tion of OEA and GW6471 30 minutes prior to ethanol
andwater access, and consumptionwas recorded over 24
hours. Both ethanol and water intake (g/kg) were calcu-
lated at different time intervals.
Statistical analyses
All data in the graphs are expressed as the mean ± SEM.
The different experiments included 6–10 animals per
treatment according to the assay. Statistical analyses of
the results were performed with one- and two-way
ANOVA followed by multiple comparison tests (Dunnett’s
test). A P-value below 0.05 was considered statistically
significant. All analyses were performed with the com-
puter program GraphPad Prism version 5.04 (GraphPad
Software Inc., San Diego, CA, USA).
RESULTS
Effects of ethanol administration on plasma and tissue
levels of OEA
To determine whether ethanol influenced OEA mobiliza-
tion, we evaluated the time course of the effects of acute
ethanol administration on the OEA levels in the plasma
and various peripheral tissues and brain areas over a
period of 240 minutes. Single ethanol injections (4 g/kg;
i.p.) resulted in rapid and marked elevations in plasma
ethanol levels (F4,50 = 131.6,P < 0.001) thatwere signifi-
cant at 45, 90and240minutes after administration com-
pared with the zero time control group (***P < 0.001)
(Fig. 1a). Decreases in plasma ethanol concentrations
were evident 8 hours after the administrations, and the
control levelswere re-establishedwithin the first 24hours
(data not shown). Because plasma ethanol levels
remained stable for 240 minutes, we selected the times of
0, 45, 90 and 240minutes for the analyses of OEA in the
plasma and tissues. A one-way ANOVA detected a signifi-
cant effect of the plasma OEA response to ethanol admin-
istration (F3,41 = 11.55, P < 0.001) due to significant
increases at 90 (**P < 0.01) and 240 minutes
(***P < 0.001) (Fig. 1b).
Additionally, we evaluated whether OEA influenced
ethanol levels. We found similar plasma ethanol concen-
trations after a single ethanol administration (4 g/kg; i.p.)
to rats pre-treated with vehicle or OEA (5 mg/kg) (Sup-
porting Information Fig. S1), indicating that OEA admin-
istration does not result in alterations in ethanol
pharmacokinetics in the 0–240 minutes post-injection
interval.
As shown in Table 1, acute ethanol also led to eleva-
tions in the OEA levels in the peripheral tissues and brain
areas (small intestine: F3,41 = 6.65, P = 0.001; liver:
F3,41 = 4.29, P = 0.011; NAc: F3,41 = 3.21, P = 0.034;
and cerebellum: F3,41 = 9.44, P < 0.001). In the small
intestine, the OEA increase was apparent at 45 minutes
(**P < 0.01) after ethanol administration, and the OEA
levels returned to the control value at 240minutes. In the
liver, OEA remained at control levels for the first 45
minutes, peaked at 90 minutes (*P < 0.05) and returned
to normal levels at 240 minutes. Similarly, ethanol
resulted in increases in OEA in the NAc at 45 and 90
minutes after its administration (*P < 0.05) and in the
cerebellum at 90 minutes (***P < 0.001). These results
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suggest that the intestine and NAc were the tissues in
which the ethanol-associated increases in OEA occurred
most quickly.
To evaluate the effects of chronic ethanol exposure
and withdrawal on plasma OEA levels, Wistar rats were
maintained on an ethanol-containing liquid diet for 21
days. The animals displayed a significant increase in
plasma ethanol concentration at the end of the liquid diet
exposure (###P < 0.001) (Fig. 1c). This rise remained
evident 6 hours into withdrawal (##P < 0.01). Regarding
the plasma OEA levels, long-term ethanol exposure pro-
duced a significant increase (##P < 0.01) (Fig. 1d). In the
plasma, this elevation was also evident following 6 and
12 hours of withdrawal, but was only significantly differ-
ent from the control group at 6 hours (#P < 0.05).
Effects of OEA on ethanol consumption
To examine whether OEA affects the ethanol consump-
tion, we used the two-bottle choice paradigm. OEA
(5 mg/kg) administration significantly decreased ethanol
intake relative to the vehicle group (F1,60 = 26.50,
P < 0.001), and significant decreases were observed at all
time points (**P < 0.01) (Fig. 2a). Next, because OEA is a
PPAR-α agonist, we tested whether the PPAR-α antago-
nist GW6471 was able to reverse the decrease in ethanol
consumption caused by OEA. As shown in Fig. 2a,
GW6471 antagonized the decrease in ethanol consump-
tion that was produced by OEA (F3,21 = 2.81, P = 0.025).
Because GPR119 has been reported as a novel OEA
target, we also evaluated whether the GPR119 receptor
agonist PSN375963 produced similar effects than OEA
on ethanol consumption. However, as shown in Fig. 2b,
PSN375963 (0.1 and 10 mg/kg) did not affect ethanol
intake at all time points evaluated. Similarly, this com-
pound had no effect on ethanol self-administration (Sup-
porting Information Fig. S2).
In addition, water consumption was not affected by
none of the treatments tested (Supporting Information
Fig. S3).
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Figure 1 Effects of acute and chronic
ethanol administration on the plasma levels
of ethanol and oleoylethanolamide (OEA)
in rats.Time course of the effects of acute
ethanol (4 g/kg; i.p.) at 0, 45, 90 and 240
minutes on plasma levels of ethanol (a) and
OEA (b). Effects of a 21-day exposure to an
ethanol–liquid diet and withdrawal (meas-
ured at 6- and 12-hour time points follow-
ing the removal of the ethanol–liquid diet)
on plasma levels of ethanol (c) and OEA
(d). The data are presented as the
mean ± standard error of the mean
(n = 6–8 determinations per group).
**P < 0.01 and ***P < 0.001 denote signifi-
cant differences compared with the control
zero time group. #P < 0.05, ##P < 0.01 and
###P < 0.001 denote significant differences
compared with the vehicle group.
EtOH = ethanol; WD = withdrawal
Table 1 Effects of ethanol administration on OEA levels in various tissues.
Tissue
Time after administration (min)
0 45 90 240
Small intestine 148.9 ± 41.8 595.4 ± 66.2** 398.1 ± 124.4 128.1 ± 25.3
Liver 38.4 ± 5.1 34.6 ± 2.0 82.5 ± 17.9* 38.4 ± 9.1
Nucleus accumbens 128.1 ± 67.4 610.7 ± 108.8* 582.6 ± 209.4* 265.7 ± 21.6
Cerebellum 248.2 ± 19.4 420.7 ± 75.5 610.8 ± 96.6*** 164.4 ± 17.9
Effects of acute intraperitoneal administration of ethanol (4 g/kg) on OEA levels (pmol/g of tissue) in small intestine, liver and brain sections (nucleus
accumbens and cerebellum) were measured at 0, 45, 90 and 240 minutes after injection. Data are means ± standard error of the mean (six to eight
determinations per group). *P < 0.05, **P < 0.01 and ***P < 0.001 denote significant differences compared with zero time group.
OEA = oleoylethanolamide.
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Effects of OEA on ethanol self-administration
Next, we examined whether OEA affects ethanol self-
administration. Wistar rats trained to self-administer 10
percent ethanol received injection of various doses of OEA
(1, 5 and 20 mg/kg). OEA administration significantly
decreased ethanol self-administration relative to the
control condition (F3,31 = 3.42, P = 0.031), and signifi-
cant decreases were observed after the administration of
both 5 and 20 mg/kg of OEA (*P < 0.05) (Fig. 3a). These
effects were also observed for sucrose (F3,31 = 10.71,
P < 0.001) after the administration of both 5 (*P < 0.05)
and 20 mg/kg of OEA (***P < 0.001) (Fig. 3b). Similarly,
systemic administration of Wy-14643 reduced ethanol
self-administration at doses of 20 and 40 mg/kg
(*P < 0.05) (Fig. 3c).
Additionally, Wy-14643 treatment was evaluated in
behavioral tests and doses of 5 and 20 mg/kg did not
affect locomotion and did not induce anxiety-like
behaviors (Supporting Information Fig. S4).
Because OEA reduces food intake through a peripheral
mechanism,but reports exists about its ability tomodulate
central dopaminergic pathways, we studied the effects of
OEA when injected centrally and in animals with chemi-
cal sensory deafferentation. Because NAc was found to
display rapid variations in OEA levels following ethanol
injection,we first evaluated the effects of repeated ethanol
administration on theOEA response to ethanol challenge.
The effects of repeated ethanol treatment (2 g/kg; i.p., and
every other day for 14 days) onNAcOEA levels are shown
in Fig. 4a. During baseline sample collection dialysate
OEA levels were 1.412 ± 0.037 nM, and no trend toward
an increase or decrease in levels was observed during this
period. Relative to these baseline levels, dialysate OEA
contentwas significantly enhanced after anacute ethanol
challenge (2 g/kg; i.p.) (F12,43 = 2.04, P = 0.025). This
increase began approximately 60 minutes after ethanol
challenge and progressively increased over the course of
the subsequent 60minutes. During the final hour of sam-
pling, OEA levels were significantly higher as compared
with baseline (**P < 0.01), reaching a maximum of 134
percent of baseline 120 minutes after injection.
Next, we evaluated the effects of the injection of OEA
into NAc on ethanol self-administration. As shown in
Fig. 4b, the injection of OEA into the NAc did not modify
ethanol self-administration. Similarly, central infusions
into the lateral ventricles of different doses of Wy-14643
(1 and 10 μg) had no effects on ethanol self-
administration (Fig 4c).However, sensorydeafferentation
with the neurotoxin capsaicin abolished both OEA- and
Wy14643-induced reduction of operant responding for
ethanol but not the reduced responding induced by
the cannabinoid receptor antagonist/inverse agonist
rimonabant (Fig. 4d) that acts centrally to reduce alcohol
self-administration.
Effects of OEA on conditioned reinstatement and
alcohol deprivation
We next examined the effects of OEA and Wy-14643 as
modulators of the operant responses elicited by the con-
textual stimuli associated with ethanol. Reinstatement
was induced by presenting cues that were associated with
ethanol delivery during training. The operant responses
induced by the ethanol-associated stimuli (S+/CS+) were
robustly increased to 19.4 ± 2.6 presses per session,
which was significantly different from the behaviors elic-
ited on the last day of extinction (4.5 ± 0.7 responses;
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Figure 2 The effects of oleoylethanolamide (OEA) on alcohol
intake are mediated by peroxisome proliferator-activated receptor-
alpha (PPAR-α).The effects of OEA (5 mg/kg) on voluntary alcohol
intake in a two-bottle choice paradigm were prevented by pre-
treatment with the synthetic PPAR-α antagonist GW6471 (1 mg/kg)
(a). The GPR119 receptor agonist PSN375963 (0.1 and 10 mg/kg)
had no effect on voluntary alcohol intake (b).The data are presented
as the mean ± standard error of the mean (n = 8–10 determinations
per group). **P < 0.01 denotes significant differences compared with
the control group. GW = GW6471; PSN = PSN375963
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Figure 3 Effects of oleoylethanolamide
(OEA) on ethanol self-administration.
Acute i.p. injection of OEA-reduced
operant responses for 10 percent ethanol
(a) and a solution containing 10 percent
sucrose (b) at 5 and 20 mg/kg. Similarly,
systemic administration of Wy-14643
reduced ethanol self-administration at
doses of 20 and 40 mg/kg (c).The data are
presented as the mean ± standard error of
the mean (n = 8–10 determinations per
group). *P < 0.05 and ***P < 0.001 denote
significant differences compared with the
respective control group
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Figure 4 Site of action of oleoylethanolamide (OEA) on alcohol self-administration. Dialysate OEA content was significantly enhanced after
an acute ethanol challenge (2 g/kg; i.p.). In NAc of mice previously exposed to repeated ethanol treatment (2 g/kg every other day for 14 days).
Ethanol injection is indicated by arrow at time point zero (a). Acute intra-accumbens injection of OEA had no effect on ethanol
self-administration (b). This lack of a central effect was also observed when the synthetic peroxisome proliferator-activated receptor-alpha
agonist Wy-14643 was injected into the lateral ventricles (c). The effect of OEA on ethanol self-administration was abolished by the
deafferentation of the vagal terminals with capsaicin (d). Capsaicin pre-treatment abolished the effects of OEA and Wy-14643 on ethanol
self-administration but did not affect the actions of the CB1 cannabinoid receptor antagonist rimonabant (SR141716A), which acts centrally
to reduce alcohol self-administration.The data are presented as the mean ± standard error of the mean (n = 8–10 determinations per group).
**P < 0.01 denotes significant differences compared with baseline OEA concentration; ***P < 0.001 denotes significant differences compared
with the control group. SR = rimonabant; VEH = vehicle; Wy = Wy-14643
Oleoylethanolamide and alcohol
© 2015 Society for the Study of Addiction Addiction Biology, 21, 859–872
867
***P < 0.001) and under the S−/CS− condition (4.4 ± 1.1
responses; ***P < 0.001, Fig. 5a). As shown in Fig. 5b,
OEA pre-treatment produced a dose-dependent reduction
in S+-induced ethanol seeking relative to the control
group (F3,31 = 9.54, P < 0.001); significant reductions
were observed at OEA doses of 5 and 20 mg/kg
(***P < 0.001). Similarly, Wy-14643 pre-treatment pro-
duced a dose-dependent reduction in S+-induced ethanol
seeking compared with the controls (F2,23 = 8.29,
P = 0.002), and significant reductions were observed at
Wy-14643 doses of 20 (*P < 0.05) and 40 mg/kg
(**P < 0.01).
We also evaluated the effects of PPAR-α agonists in an
alcohol deprivationmodel (Fig. 5c). During the final three
self-administration sessions (baseline) before ethanol
deprivation, the animals obtained an average of
33.1 ± 3.0 ethanol reinforcers per session. Ethanol dep-
rivation increased the operant responses for ethanol to
47.8 ± 4.0. OEA administration decreased ethanol self-
administration following the ethanol deprivation phase
(F2,23 = 13.79,P < 0.001), and significant decreaseswere
observed after the administration of 5 mg/kg OEA
(**P < 0.01). Similar results were observed after the
administration of 20 mg/kg Wy-14643 (*P < 0.05). The
numbers of operant responses observed after either treat-
ment were even lower than those observed in the baseline
condition (OEA: ###P < 0.001; Wy-14643: ##P < 0.01).
Effects of OEA on ethanol withdrawal symptoms
To further explore the effects of OEA on ethanol-related
behaviors, several signs of withdrawal were scored in
ethanol-dependent rats after the withdrawal of ethanol.
As shown in Fig. 6a, OEA treatment had a significant
effect on ethanol withdrawal symptoms (F1,70 = 34.13,
P < 0.001). This analysis also revealed a significant
interaction between treatment and time (F4,70 = 6.73,
P < 0.001).Thus,OEAadministration induced significant
decreases in the total scores for ethanol withdrawal signs
at 8 and 9 hours into withdrawal (***P < 0.001) com-
pared with the vehicle-treated animals. Indeed, the
administration of OEA produced significant decreases in
eachof thewithdrawal symptoms thatwere evaluated; i.e.
vocalization, head tremor and rigidity (*P < 0.05); tail
tremor (**P < 0.01); and body tremor (***P < 0.001)
(Fig. 6b).
DISCUSSION
The present results identified a prominent role for OEA as
a homeostatic signal that controls multiple aspects of the
physiological adaptations to alcohol exposure. OEA pro-
duction is triggered by alcohol administration and con-
tributes to the regulation of alcohol intake, the acute
motivational response to alcohol and the onset of with-
drawal symptoms after cessation of chronic alcohol con-
sumption. Because OEA has been identified as an
intestinal satiety signal that controls hedonic value of
food (mainly fat), we cannot consider the observed
response as specific for ethanol. Moreover, OEA has been
identified already as an important mediator of the rein-
forcing properties of nicotine (Mascia et al. 2011) sup-
porting this general role of control of the hedonic
homeostasis.
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Figure 5 Effects of oleoylethanolamide
(OEA) on conditioned reinstatement and
the effects of alcohol deprivation. Condi-
tioned responses to ethanol-associated
cues (a) were reduced by the administra-
tion of both OEA (1, 5 and 20 mg/kg) and
the peroxisome proliferator-activated
receptor-alpha receptor agonist Wy-14643
(20 or 40 mg/kg). (b) i.p. administration of
OEA or Wy-14643 reduced the enhance-
ment of the operant ethanol responses that
were observed after a 5-day ethanol dep-
rivation period (c).The data are presented
as the mean ± standard error of the mean
(n = 8–10 determinations per group).
*P < 0.05, **P < 0.01 and ***P < 0.001
denote significant differences compared
with the respective control group. #P < 0.05,
##P < 0.01 and ###P < 0.001 denote signifi-
cant differences compared with the last day
of baseline period
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The first interesting finding of the present study was
the induction of OEA mobilization following acute expo-
sure to alcohol. This effect was observed in different
tissues and was detected in plasma samples. The intensi-
ties and time courses of alcohol-induced OEA production
were time and tissue dependent, and the small intestine
(jejunum) and the NAc were the first tissues in which
OEA accumulation was detected. In the NAc, the time
course of OEA release (Fig. 4a) paralleled that of classical
transmitters activated by ethanol. These transmitters can
activate receptors capable of triggering OEA formation
through the NAPE-PLD pathway. Alcohol might recruit
either catecholaminergic, cholinergic or glutamatergic
neurons (Spanagel 2009), which in turn might trigger
receptor-dependent OEA activation (Stella & Piomelli
2001). A contribution of a modification of FAAH activity
induced by the presence of ethanol was discarded in pre-
vious studies (Ferrer et al. 2007). The mechanisms by
which alcohol triggers OEAmobilization in the periphery
might be related to the dependence of OEA production on
sympathetic activity (Fu et al. 2011). Alcohol is an acti-
vator of the sympathetic nervous system (for review see
Spanagel 2009) and sympathetic activation has been
found to increase OEA production not only in the intes-
tine but also in metabolically relevant organs such as
adipose tissue (Guzmán et al. 2004; LoVerme et al. 2006;
Fu et al. 2011). Thus, alcohol-enhanced activation of
sympathetic output might be responsible for the observed
increases in OEA. Because the plasma and liver OEA
elevations were delayed relative to the intestinal accumu-
lation, we infer that this effect is secondary to the activa-
tion of primary targets of sympathetic innervation. In
the brain, the rapid response of the NAc, which was
observed by monitoring tissue contents, is suggestive of a
direct action of alcohol on the brain. In this organ,
alcohol might recruit either catecholaminergic,
cholinergic or glutamatergic neurons (Spanagel 2009),
which in turnmight trigger receptor-dependent OEA acti-
vation (Stella & Piomelli 2001). This hypothesis needs to
be tested in future studies. Finally, plasmaOEA levels were
found to be constantly elevated during chronic alcohol
consumption. The removal of alcohol from the diet
induced a decrease in OEA levels that paralleled the
decrease in alcohol level, thus indicating a tight associa-
tion between OEA formation and the presence of alcohol
in the body. As we discuss later, the disappearance of OEA
is related to overt alcohol withdrawal symptoms, which
supports the adaptive nature of OEA as an alcohol-driven
homeostatic signal that is necessary to adapt the body to
the presence of ethanol.
OEA has been linked to physiological responses that
are associated with high-calorie intake, including the
control of motivational aspects of eating and metabolic
adaptations to high-calorie foods (Piomelli 2003;
Schwartz et al. 2008). Based on this hypothesis, we
studied whether alcohol-induced OEA regulated alcohol
intake. Confirming this hypothesis, we found that the
administration of either OEA or PPAR-α agonists reduced
alcohol intake and self-administration.The action of OEA
effect was dependent on the presence of PPAR-α, because
it was blocked by a selective PPAR-α antagonist. This
effect was extended to sucrose and was not related to the
activation of an additional OEA target, the GPR119
receptor (Overton et al. 2006).
Overall, these findings indicate that, as has been
described for fats and high-calorie foods (Rodríguez de
Fonseca et al. 2001; Fu et al. 2003, 2007; Piomelli
2013), OEA is capable of modulating both the consump-
tion and motivational responses to alcohol, which is also
highly caloric. These motivational aspects extend to the
control of the effects of contextual memories associated
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Figure 6 Effects of oleoylethanolamide (OEA) on ethanol with-
drawal symptoms. Acute administration of OEA reduced the global
ethanol withdrawal scores that were measured between 6 and 12
hours into withdrawal (a).This effect was observed on each of the
symptoms that were evaluated (b). The data are presented as the
mean ± standard error of the mean (n = 8–10 determinations per
group). *P < 0.05, **P < 0.01 and ***P < 0.001 denote significant dif-
ferences compared with the vehicle-treated group
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with alcohol consumption in alcohol relapse. Interest-
ingly, both OEA and PPAR-α agonists reduced cue-
induced reinstatement of alcohol consumption, which
suggests that, following extinction, OEA has the ability to
curb motivational memories that are associated with the
effects of alcohol. Although OEA has been demonstrated
to strengthen memory consolidation (Campolongo et al.
2009), the present results suggest that it can also modu-
late the impact of a recalled memory on motivational
drives. However, this hypothesis needs to be confirmed as
a peripheral-driven satiety/anhedonic response derived of
the activation of the vagus nerve by OEA might counter-
act the motivational contextual responses associated
with alcohol intake.
Following the strategy used to determine the site
of action of FAEs in the suppression of food intake
(Rodríguez de Fonseca et al. 2001; Gómez et al. 2002), we
searched for the site of action of OEA on alcohol self-
administration. As described for food intake, the effects of
OEA on alcohol self-administration and cue-induced
reinstatement were found to be dependent on the integ-
rity of the peripheral sensory system. Capsaicin-induced
deafferentation of the small intestine abrogated these
effects and left the centrally mediated effects of com-
pounds, such as the CB1 receptor antagonist rimonabant
(which reduces alcohol self-administration by targeting
the prefrontal cortex) intact (Hansson et al. 2007). This
finding was confirmed by the lack of effects of i.c.v. injec-
tions of PPAR-α agonist into alcohol self-administering
animals. Thus, we hypothesize that alcohol, as has been
described for high-calorie foods, might activate ascending
sensory pathways that ultimately inhibit the motiva-
tional aspects of alcohol intake by releasing OEA in the
intestine (Rodríguez de Fonseca et al. 2001; Piomelli
2003). The participation of the nucleus of the solitary
tract and its connections with the oxytocinergic (Gaetani
et al. 2010) and histaminergic (Provensi et al. 2014)
systems that further mediate OEA-induced feeding inhi-
bition, will be addressed in future studies.
Following the observation of the decrease in plasma
OEA with ethanol withdrawal, we observed that this
decline paralleled the onset of alcohol withdrawal symp-
toms. OEA injection at the beginning of withdrawal (i.e.
the time at which OEA levels dropped) induced a clear
reduction in the severity of the behavioral symptoms
associated with withdrawal. At the present time, we do
not know whether this finding reflects an intrinsic ability
of OEA to reduce the hyper-excitability associated with
ethanol withdrawal. Although OEA has been found to
interact with ion channels to regulate excitability, we
cannot rule out further actions in targets that are
recruited by alcohol withdrawal including the peptidergic
and classical neurotransmitter systems. However, the
reductions of the motivational effects of ethanol-
associated cues and reductions of the severities of alcohol
withdrawal symptoms by the single molecule OEA
provide a unique profile for the future design of therapies
for alcoholism.
In conclusion, our results revealed that OEA is an
endogenous signal that participates in the homeostatic
adaption to alcohol. The actions of OEA cover multiple
physiological aspects and open a potential new path for
the development of effective therapies for alcoholism.
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